These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 17333089

  • 1. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.
    Vaccine; 2006 Jul 17; 24(29-30):5690-9. PubMed ID: 16735083
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A, Edmunds WJ.
    Vaccine; 2004 Oct 22; 22(31-32):4203-14. PubMed ID: 15474710
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
    Claes C, Reinert RR, von der Schulenburg JM.
    Eur J Health Econ; 2009 Feb 22; 10(1):25-38. PubMed ID: 18379830
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U.
    Scand J Infect Dis; 2008 Feb 22; 40(9):721-9. PubMed ID: 18712627
    [Abstract] [Full Text] [Related]

  • 8. Economic evaluation of pneumococcal conjugate vaccination in Finland.
    Salo H, Sintonen H, Nuorti JP, Linna M, Nohynek H, Verho J, Kilpi T.
    Scand J Infect Dis; 2005 Feb 22; 37(11-12):821-32. PubMed ID: 16308215
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ.
    Vaccine; 2007 May 04; 25(18):3669-78. PubMed ID: 17360082
    [Abstract] [Full Text] [Related]

  • 12. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).
    Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J.
    Vaccine; 2007 Mar 22; 25(13):2420-7. PubMed ID: 17049677
    [Abstract] [Full Text] [Related]

  • 13. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS.
    Vaccine; 2007 Jul 20; 25(29):5390-8. PubMed ID: 17583392
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
    Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB.
    Pediatr Infect Dis J; 2006 Jun 20; 25(6):494-501. PubMed ID: 16732146
    [Abstract] [Full Text] [Related]

  • 16. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.
    Vaccine; 2004 Mar 12; 22(9-10):1138-49. PubMed ID: 15003641
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
    Giglio ND, Cane AD, Micone P, Gentile A.
    Vaccine; 2010 Mar 08; 28(11):2302-10. PubMed ID: 20064478
    [Abstract] [Full Text] [Related]

  • 18. [Costs of pneumococcal infections and cost evaluation of heptavalent conjugate vaccine].
    D'Alessandro D.
    Ann Ig; 2002 Mar 08; 14(6 Suppl 7):43-8. PubMed ID: 12638364
    [Abstract] [Full Text] [Related]

  • 19. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E, Salleras L, Gisbert R, Domínguez A, Timoner E, Ibáñez D, Prat A.
    Vaccine; 2005 Mar 18; 23(17-18):2342-8. PubMed ID: 15755625
    [Abstract] [Full Text] [Related]

  • 20. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P, Black S, Borrow R, Pearce D.
    Clin Ther; 2009 Oct 18; 31(10):2152-69. PubMed ID: 19922887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.